Skip to content

US · DNA · BIOTECHNOLOGY

Ginkgo Bioworks Holdings, Inc. (DNA) intrinsic value and stock valuation

$7.46as of 2026-11-21 · Mkt cap 612.09M

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ginkgo Bioworks Holdings, Inc. DCF and intrinsic value

InvestorsCraft values DNA with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from DNA’s statements →

Ginkgo Bioworks Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02210 ginkgo.bio

How the business is doing

Fiscal 2019–2025, USD

Revenue
$170.2M+17.3% 5y CAGRd
20192025
Net income
-$-312.76M
20192025
Free cash flow
-$-178.72M
20192025
Total equity
$508.6M+1.6% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$170.2M$227M$251.5M$477.7M$313.8M
Operating income-$-315.28M-$-559.76M-$-864.41M-$-2.21B-$-1.83B
Net income-$-312.76M-$-547.03M-$-892.87M-$-2.1B-$-1.83B
EPSd-$-5.64M-$-10.54M-$-18.37M-$-50.12M-$-53.81M
Operating cash flow-$-171.06M-$-319.58M-$-295.5M-$-252.2M-$-253.82M
Capital expenditure-$-7.67M-$-62.54M-$-40.8M-$-52.27M-$-56.52M
Free cash flow-$-178.72M-$-382.13M-$-336.3M-$-304.47M-$-310.34M
Total assets$1.12B$1.38B$1.67B$2.54B$2.07B
Total debt$439.9M$467.7M$239.3M$442.6M$23M
Net debt$272.7M-$-93.84M-$-704.76M-$-873.2M-$-1.53B
Total equity$508.6M$716.1M$1.1B$1.74B$1.57B
Cash and short-term investments$422.6M$561.6M$944.1M$1.32B$1.55B
Income statement
20252024202320222021
Revenue$170.2M$227M$251.5M$477.7M$313.8M
Cost of revenue$31.5M$38.6M$54M$204.2M$129.7M
Gross profit$138.6M$188.5M$197.5M$273.5M$184.2M
Research and development expenses$243.8M$424.1M$580.6M$1.05B$1.15B
Selling, general and administrative expenses$183.3M$246.2M$385M$1.43B$863M
Other expenses$26.9M$78M$96.2M$0.00$0.00
Operating expenses$453.9M$748.3M$1.06B$2.48B$2.01B
Cost and expenses$485.4M$786.8M$1.12B$2.69B$2.14B
Interest income$22.6M$38.6M$57.2M$20.3M$840K
Interest expense$0.00$90K$90K$110K$2.37M
Depreciation and amortization$59M$63M$71.6M$61.6M$29.1M
Ebitda-$-254.61M-$-484.39M-$-821.29M-$-2.06B-$-1.81B
Operating income-$-315.28M-$-559.76M-$-864.41M-$-2.21B-$-1.83B
Total other income/expenses, net$1.68M$12.3M-$-28.53M$87.6M-$-9.65M
Income before tax-$-313.6M-$-547.51M-$-892.94M-$-2.12B-$-1.84B
Income tax expense-$-840K-$-480K-$-70K-$-15.03M-$-1.48M
Net income-$-312.76M-$-547.03M-$-892.87M-$-2.1B-$-1.83B
Weighted average shares outstanding$55.5M$51.9M$48.5M$41.9M$33M
Weighted average diluted shares outstanding$55.5M$51.9M$48.6M$42M$34M
Balance sheet
20252024202320222021
Cash and short-term investments$422.6M$561.6M$944.1M$1.32B$1.55B
Net receivables$24M$22.4M$17.9M$84M$149.9M
Inventory$0.00$0.00$50K$4.36M$3.36M
Total current assets$471.8M$602.7M$1B$1.45B$1.72B
Property, plant and equipment, net$528.7M$598.2M$395M$718.8M$145.8M
Goodwill and intangible assets$56.9M$72.5M$132M$171.3M$43M
Long-term investments$15.1M$48.7M$77.9M$111.8M$115.2M
Total non-current assets$647.9M$774.7M$663.6M$1.09B$347.9M
Total assets$1.12B$1.38B$1.67B$2.54B$2.07B
Accounts payable$10.6M$14.2M$9.32M$10.5M$8.19M
Short-term debt$22.8M$29M$17.5M$29.3M$750K
Deferred revenue$20M$30.6M$48.5M$47.8M$33.2M
Total current liabilities$96M$107.3M$163.9M$173M$134.8M
Long-term debt$417.1M$438.8M$221.8M$413.3M$22.3M
Deferred revenue, non-current$75.2M$98.8M$158.1M$174.8M$156M
Total non-current liabilities$515.1M$554.1M$404.3M$630.1M$368.9M
Capital lease obligations$439.9M$467.7M$239.3M$442.6M$23M
Total liabilities$611.1M$661.4M$568.2M$803M$503.6M
Common stock$10K$10K$10K$190K$160K
Retained earnings-$-6.15B-$-5.84B-$-5.29B-$-4.4B-$-2.3B
Accumulated other comprehensive income (loss)$1.85M-$-1.81M$1.48M-$-2.63M-$-1.72M
Total equity$508.6M$716.1M$1.1B$1.74B$1.57B
Total investments$270.5M$48.7M$77.9M$111.8M$115.2M
Total debt$439.9M$467.7M$239.3M$442.6M$23M
Net debt$272.7M-$-93.84M-$-704.76M-$-873.2M-$-1.53B
Cash flow statement
20252024202320222021
Net income-$-312.76M-$-547.03M-$-892.87M-$-2.11B-$-1.84B
Depreciation and amortization$59M$63M$71.6M$42.6M$29.1M
Stock-based compensation$81.6M$112.3M$229.9M$1.93B$1.61B
Change in working capital-$-44.09M-$-89.67M$29.8M-$-37.01M-$-61.54M
Accounts receivable-$-1.47M-$-4.72M$50.1M$55M-$-114.09M
Inventory$0.00$0.00$0.00$160K-$-630K
Accounts payable-$-2.99M$4.77M-$-1.18M-$-10.84M-$-2.25M
Net cash provided by operating activities-$-171.06M-$-319.58M-$-295.5M-$-252.2M-$-253.82M
Investments in property, plant and equipment-$-7.67M-$-62.54M-$-40.8M-$-52.27M-$-56.52M
Acquisitions, net$0.00-$-5.4M-$-38.55M$26.7M-$-12.04M
Net cash used for investing activities-$-240.29M-$-62.24M-$-80.69M-$-67.39M-$-73.26M
Common stock issued$19.5M$80K$0.00$99.3M$0.00
Common stock repurchased$0.00$0.00-$-20K$0.00-$-25M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.8M-$-1.74M-$-3.22M$95.3M$1.53B
Net change in cash-$-393.18M-$-383.84M-$-380M-$-223.35M$1.21B
Cash at end of period$174.2M$605.7M$989.6M$1.37B$1.59B
Operating cash flow-$-171.06M-$-319.58M-$-295.5M-$-252.2M-$-253.82M
Capital expenditure-$-7.67M-$-62.54M-$-40.8M-$-52.27M-$-56.52M
Free cash flow-$-178.72M-$-382.13M-$-336.3M-$-304.47M-$-310.34M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ginkgo Bioworks Holdings, Inc.

        Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

        CEO
        Jason Kelly
        Employees
        485
        Beta
        1.78

        Explore

        Frequently asked questions

        What is the intrinsic value of Ginkgo Bioworks Holdings, Inc. (DNA)?

        Ginkgo Bioworks Holdings, Inc. (DNA) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is DNA undervalued?

        DNA trades at a price of $7.46 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.